Chenodeoxycholic acid

Drug Profile

Chenodeoxycholic acid

Alternative Names: Chenix; Chenodiol; Chenofalk; Xenbilox

Latest Information Update: 06 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dr Falk Pharma
  • Developer Leadiant Biosciences; Solvay
  • Class Choleretics; Cholic acids; Gallstone therapies; Gastrokinetics; Irritable bowel syndrome therapies
  • Mechanism of Action Cholesterol modulators; Cholesterol synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cerebrotendinous xanthomatosis; Inborn error metabolic disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cholestasis
  • Preregistration Cerebrotendinous xanthomatosis

Most Recent Events

  • 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences
  • 01 Nov 2015 Preregistration for Cerebrotendinous xanthomatosis in European Union (PO) (Centralised procedure)
  • 23 Jun 2015 Chenodeoxycholic acid is still in Preregistration for Cerebrotendinous xanthomatosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top